Riding the Wave: India's Healthcare Surge & the Sole Listed TPA You Need to Know
The Indian healthcare landscape is evolving rapidly, driven by increasing awareness, rising medical costs, and a growing middle class seeking financial security against health emergencies.
Amidst this transformation, Third-Party Administrators (TPAs) like Medi Assist Healthcare Services Ltd are emerging as pivotal, albeit often overlooked, players. But can investing in a TPA truly be a proxy for riding India's healthcare wave?
Let's delve into Medi Assist's business, industry dynamics, and future prospects to uncover the answer.
Understanding the TPA Ecosystem: The Unsung Heroes of Health Insurance
Medi Assist Healthcare Services Limited, established in 2000, operates as a holding company providing TPA services to insurance companies through its wholly-owned subsidiaries: Medi Assist TPA, Medvantage TPA (from February 13, 2023), and Raksha TPA (from August 25, 2023). Recently, on 1st July 2025, completed 100% acquisition of Paramount TPA.
So, what exactly does a TPA do? A TPA is an organization that processes health insurance claims for insurance companies. Their services extend beyond mere claim processing to include policy administration, customer service, and network management. Essentially, they act as the crucial link between insurers, healthcare providers, and policyholders, streamlining complex processes.
Core Functions of a TPA:
Benefits of TPAs across the Ecosystem:
For Insurers:
Drive operational efficiency by outsourcing claims and administration, allowing focus on core activities like product development and risk management.
Deliver cost savings through economies of scale and efficient processes.
Aid in fraud prevention and provide real-time analytics dashboards to monitor claim patterns.
For Healthcare Providers:
Simplify billing, handle claim submissions and payments, and reduce administrative burdens.
Increase patient volume by directing policyholders to network providers.
Ensure timely reimbursements, improving cash flow.
Manage the growing complexity of new insurance policies, alleviating this burden from hospitals.
For Policyholders:
Offer improved customer experience and transparency by providing real-time updates on claim status.
The Business Model: How TPAs Generate Revenue
Primary Revenue Source: Contrary to a common misconception that TPAs only charge during claim reimbursement, they primarily earn a flat percentage charge on the "Premium Under Management" (PUM). This premium is collected by the insurers who are clients of TPAs like Medi Assist.
Medi Assist's Fee Structure: In Medi Assist's case, it charges approximately 2-5.5% flat commission fees depending on the product type it supports.
FY25 Financials: For FY25, Medi Assist's PUM was INR 21,107 Crores, and its corresponding revenue was approximately INR 723 Crores, implying a yield of ~3.4% (723/21107).
Correlation and Tailwinds: This indicates a direct correlation between PUM growth and Medi Assist's revenue, making medical inflation and rising premiums a natural tailwind for the company.
Industry Tailwinds: A Long Runway for Growth
The prospects for the healthcare and TPA industries in India appear robust, fueled by several strong tailwinds:
Health Insurance Dominance: Health insurance was the largest and fastest-growing segment in India's general/non-life insurance category between 2017-2022, a trend expected to continue due to medical inflation consistently exceeding 10% (double the general inflation rate).
Low Penetration & Out-of-Pocket Expenses: The proportion of lives covered under health insurance in India (excluding government schemes) is still below 25%. This low penetration suggests a significant growth runway, as individuals will increasingly struggle to bear expensive medical costs out-of-pocket. The number of lives covered is forecasted to grow at a CAGR of 14.96% from FY2022-2028.
Segment-Specific Growth: Both retail and group health insurance segments are poised for substantial growth. The Gross Health Premium Service increased by approximately 19% year-on-year across retail, group, and government segments, with faster growth anticipated for the Group and Retail segments. This is particularly good news for TPAs, which dominate these spaces, especially the Group segment.
Increasing TPA Penetration: TPA-serviced premiums as a percentage of the total industry premium are projected to rise from ~53% to 61% by FY28. This is driven by the increasing volume and complexity of claims, as well as the value proposition TPAs offer. The Group segment, in particular, is expected to see a much higher percentage increase, significantly benefiting the TPA industry. Total premium serviced by TPAs is forecasted to grow at a CAGR of 25.14% from FY2022-2028, with Group segment growing at 29.19% and Retail at 20.71%.
Given the current low health insurance penetration and the value-added services TPAs provide, the industry is set for significant tailwinds, with a forecasted growth rate of around 20% CAGR for the next few years, and TPA penetration expected to grow even faster, potentially greater than 20% CAGR
Medi Assist's Performance: A Leader in the Making?
Now, let's assess Medi Assist's individual performance and strategic positioning.
Business Growth & Profitability:
Medi Assist has consistently demonstrated strong financial performance, growing its revenue at approximately 18% over the last five years while maintaining robust operating profit margins (OPM) above 22%. Although net profit margins have typically hovered around 10-12%, net profit itself has expanded at a ~20% CAGR during the same period. Management affirms that OPMs of 22-24% are sustainable long-term, with any minor fluctuations typically occurring during acquisition integration phases.
A critical driver of this growth is Premium Under Management (PUM), which has expanded impressively at a ~30% CAGR over the past three years. Notably, Medi Assist operates with negative working capital days, as it collects fees upfront. This efficient cash conversion, combined with its ability to generate a decent amount of Free Cash Flow (FCF) every year, positions the company to potentially fund future acquisitions without consistently relying on external capital raises.
Leadership Position, Financial Health & Client Retention:
Medi Assist holds a leading position in the Indian health insurance market. It currently manages 19.6% of the Health Insurance (Group+Retail) premium, which is projected to increase to ~23.6% post-Paramount acquisition. Within TPA service revenue, Medi Assist leads with ~30% market share, expected to grow to ~36% after the Paramount acquisition. Their closest competitor, Vidal, holds significantly less market share (~13% within TPA service).
Medi Assist's financial parameters, including EBITDA Margin (23%), PAT Margin (14.51%), ROE (19.63%), and ROCE (21.67%), are significantly higher than those of its competitors as of FY2023. The management attributes these superior margins to their scalable tech platform, which enables margin expansion post acquisitions, allowing them to operate at traditional margins (21-24%) within 3-4 quarters.
The company also boasts impressive client retention rates, with ~95% in the group segment and many group clients maintaining relationships for over a decade.
Cost Leadership & Tech Focus:
Medi Assist's operational efficiency is evident in its ability to scale without proportional increases in overhead. Between FY21 and FY24, the total number of claims intimated (excluding Raksha) surged from 3.1 million to 7.63 million—a robust 34.5% CAGR—without a significant jump in employee strength. The company aims to sustain employee expenses at around 40% of total revenue.
Medi Assist's commitment to technology extends to strengthening its fraud detection capabilities, having identified substantial fraud values, exceeding INR 500 million in half-year FY2023 alone. A testament to their innovation is their in-house "Raksha Prime" product. This proprietary AI-powered solution allows patients to leave hospitals immediately after discharge by accurately predicting claim approval amounts, thereby saving 6-7 hours of waiting time. This transformative potential could be a significant game-changer for both hospitals and patients.
This could be a game-changer for both hospitals and patients if successfully scaled.
A particularly noteworthy development is the recent partnership between Star Health Insurance and Medi Assist to Transform Claims through AI and Digital Innovation. This collaboration, aimed at enhancing speed, accuracy, and consistency while combating fraud, waste, and abuse, speaks volumes about Medi Assist's technological prowess. This is especially significant given that Star Health Insurance operates its own in-house TPA, making this partnership a strong endorsement of Medi Assist's advanced tech offerings despite being, indirectly, a competitor.
You can read more about this partnership here
Company Management & Vision: A Tech-First Approach
The management team appears capable and invested. Chairman Dr. Vikram Chhatwal, an initial promoter, has been with the company since its early days.
Current CEO Satish Gidugu, who joined in 2013 as CTO before becoming CEO, brings a strong technology background, having previously worked as CTO at redBus, focusing on high availability and cloud infrastructure. This background underpins Medi Assist's emphasis on its "Tech Estate" as the core driver of its sustainable 20%+ margins, suggesting the company functions more like a tech firm than a traditional TPA.
Global Precedent: The US Market Analogy
US TPA Market (2023):
Total direct health insurance premium written: Approximately $1.4 trillion USD.
Corresponding TPA market revenue: Around $158 billion USD.
TPA market size as a percentage of total direct premium: Roughly 11% ($158/$1400).
Indian TPA Market (2023):
Total health insurance premium written: Approximately INR 97,880 Crores.
TPA market revenue: Around INR 2,000 Crores.
Current TPA market size as a percentage of total insurance premium: About 2% (2000/97880).
Opportunity for India: This significant gap suggests a substantial opportunity for the Indian TPA market to expand, potentially increasing from the current 2% to 5% of the total insurance premium.
Key Risks & Weaknesses: A Balanced View
While the prospects are compelling, it's crucial to acknowledge the potential risks:
In-house TPA Threat: A primary concern is insurers opting for in-house TPAs to save the ~3-5% cost. However, Medi Assist's management is confident that their combination of technology, access, cashless capabilities, and predictable management of medical in patient services makes them difficult to replicate. The recent partnership between Star Health Insurance (which operates its own in-house TPA) and Medi Assist serves as living proof of this statement by management.
They have maintained high retention rates (~95%) with almost all 27 insurers in the Group segment for years, even while increasing market share.
Client Concentration: There's a concentration risk, with the top 5 clients accounting for over 75% of revenue.
Acquisition Dependency: Medi Assist's growth strategy relies heavily on synergistic acquisitions, which inherently carry risks such as margin reduction if integration is not successful or if employee expenses rise. Historically, these acquisitions have been valued at approximately 2 times sales, as seen with Raksha for INR 120 Crores and the planned Paramount acquisition for ~INR 300 Crores. It's noteworthy that Bajaj Finserv's acquisition of Vidal, with ~INR 200 Crores in revenue, was valued at INR 325 Crores, appearing to be at a relatively lower range.
Yield Reduction: Industry consolidation or acquisitions by large corporate houses (like Bajaj Finserv acquiring Vidal) could lead to a reduction in the yield on PUM serviced (currently ~2-5.5%).
Capital Raising: The recent need to raise INR 350 Crores, diverging from earlier statements about funding the Paramount acquisition from cash on books and future generation, requires clarification from management.
It's important to remember that this is a relatively nascent industry in India, and Medi Assist is one of the first of its kind to be listed. Investors should closely monitor management's execution on PUM expansion, sustainable margins (22-25%), and continued leadership.
Valuation: Is the Opportunity Priced In?
As of 17 July 2025, Medi Assist has a market capitalization of approximately INR 3900 Crores and a net profit of INR 92 Crores, trading at around 43x P/E multiples. The absence of directly listed TPA peers in India makes benchmarking challenging.
But by keeping things very simple, post Paramount acquisition, total market share will be ~23 % and let's try to extrapolate the revenue/Net Profit for FY28, as we have a possible rough estimate for PUM FY28 from the Frost and Sullivan Research report.
Let's consider two scenarios for FY28, leveraging the Frost & Sullivan research report's PUM estimates:
Conservative Case:
Assuming Medi Assist maintains its post-Paramount acquisition market share of ~23% and a slightly lower yield rate of 2.25% (versus the usual 3.5%), with a net profit margin of 11% (against 12% currently):
Total Industry PUM (FY28E): INR 244,600 Crores
Medi Assist PUM (23% market share): INR 56,258 Crores
Revenue (2.25% yield): INR 1,266 Crores
Net Profit (11% margin): INR 139 Crores
Under this conservative scenario, using various P/E multiples, the projected CAGR returns from the current Mcap (INR 3900 Crores) would range from -4% (at 25x P/E) to 17% (at 45x P/E) by FY28.
Aggressive Case:
Assuming Medi Assist maintains its ~23% market share, but with a yield of 3.5% and a net profit margin of 12% (similar to current levels):
Total Industry PUM (FY28E): INR 244,600 Crores
Medi Assist PUM (23% market share): INR 56,258 Crores
Revenue (3.5% yield): INR 1,969 Crores
Net Profit (12% margin): INR 236 Crores
In this aggressive scenario, the projected CAGR returns from the current Mcap (INR 3900 Crores) could range from 15% (at 25x P/E) to 39% (at 45x P/E) by FY28.
Conclusion: A Promising Yet Nuanced Opportunity
Medi Assist, with its market leadership, competitive technology offerings, sustainable margins, and capable management, is exceptionally well-positioned to capitalize on the significant tailwinds in the Indian healthcare and TPA sectors.
Based on our analysis,
The likelihood of achieving a ~15% CAGR in the next three years appears very high.
Furthermore, a ~20-25% CAGR in the next three years also seems moderately to reasonably high.
However, it is crucial to acknowledge that all investments carry inherent risks. While the company's fundamentals are strong, the successful execution of its acquisition strategy and adept navigation of potential competitive shifts, particularly from in-house TPA initiatives, will be paramount.
As Murphy's Law says, anything which can go wrong will (indeed/sometimes) go wrong :)
For deeper dives and actionable investment ideas, explore our curated smallcase portfolios: candorinvesting.smallcase.com
Analyst: Vasu
Disclaimer: Registration granted by SEBI, membership of BASL, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Investment in the securities market is subject to market risks. Read all the related documents carefully before investing. This blog post is for educational purposes only and not a stock recommendation.
Read the full Disclaimer - candorinvesting.com/disclaimer